Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit

      Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit

PR Newswire

DUBLIN, March 12, 2014

DUBLIN, March 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed
that the United States District Court for the Eastern District of Virginia has
ruled that United States Patent No. RE44,048 (the '048 Patent) is invalid.
Actavis was earlier sued by Plaintiffs G.D. Searle LLC and Pfizer Asia Pacific
PTE, Ltd. for infringement of the '048 Patent in connection with its
Abbreviated New Drug Application directed to Actavis' generic version of
Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. 

Actavis intends to launch the product following the expiration of United
States Patent Nos. 5,466,823 and 5,563,165 in May 2014, pending final approval
of its Abbreviated New Drug Application by the U.S. Food and Drug
Administration (FDA). Based on available information, Actavis believes it may
be entitled to 180 days of generic market exclusivity or shared exclusivity,
subject to the FDA's determination that the product qualifies for an award of
exclusivity under the provisions of the Hatch-Waxman Act.

Celebrex^® is indicated for the treatment of osteoarthritis, rheumatoid
arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain
and primary dysmenorrhea. For the 12 months ended December 31, 2013,
Celebrex^® had total U.S. sales of approximately $2.2 billion.

About Actavis
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand
and biosimilar products. Actavis has global headquarters in Dublin, Ireland
and U.S. administrative headquarters in Parsippany, New Jersey, USA.

Actavis develops and manufactures generic, brand, branded generic, legacy
brands and Over-the-Counter (OTC) pharmaceutical products and has commercial
operations in approximately 60 countries. The Company's North American
branded pharmaceuticals business is focused principally in the Women's Health,
Urology, Gastroenterology and Dermatology therapeutic categories with a strong
pipeline of products in various stages of development. Actavis also has a
portfolio of five biosimilar products in development in Women's Health and
Oncology. Actavis Global Operations has more than 30 manufacturing and
distribution facilities around the world, and includes Anda, Inc., a U.S.
pharmaceutical product distributor.

For press release and other company information, visit Actavis' Web site at
http://www.actavis.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual
performance. Actual results may differ materially from Actavis' current
expectations depending upon a number of factors affecting Actavis' business.
These factors include, among others, the inherent uncertainty associated with
financial projections; the difficulty of predicting the timing or outcome of
product development efforts and FDA approvals or actions, if any; the
difficulty of predicting the timing or outcome of the pending patent
litigation, including potential appeals, and risks that an adverse outcome in
such litigation and appeals could render Actavis liable for substantial
damages; the impact of competitive products and pricing; the timing and
success of product launches; difficulties or delays in manufacturing; the
availability and pricing of third party sourced products and materials;
successful compliance with FDA and other governmental regulations applicable
to Actavis and its third party manufacturers' facilities, products and/or
businesses; and such other risks and uncertainties detailed in Actavis'
periodic public filings with the Securities and Exchange Commission, including
but not limited to Actavis plc's Annual Report on Form 10-K for the year ended
December 31, 2013. Except as expressly required by law, Actavis disclaims any
intent or obligation to update these forward-looking statements.

Celebrex^® is a registered trademark of Pfizer, Inc.

CONTACTS: Investors:
Lisa DeFrancesco
 (862) 261-7152

 Media:
 Charlie Mayr
 (862) 261-8030

 David Belian
 (862) 261-8141

Actavis plc logo

Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO



SOURCE Actavis plc

Website: http://www.actavis.com
 
Press spacebar to pause and continue. Press esc to stop.